Let's not forget the competitive landscape for Dimerix:
Alexion Pharmaceuticals, Inc.
Share price $124 USD
Market cap $29.13b
Amyndas Pharmaceuticals LLC
Revenue 300k/yr
Orphan drug status
http://www.fiercepharma.com/pharma/...drug-status-from-fda-and-ema-for-treatment-c3
Anthera Pharmaceuticals Inc.
Share price $3 USD
Market cap 129.7m
Avexxin ASBiogen, Inc.
Share price $296
Market cap $64b
Complexa, Inc.
Complexa’s nitro and keto-fatty-acid anti-inflammatory human cell signaling technology stems from Nobel Prize winning research and a top 10 cited scientist in the field of biochemistry and pharmacology. The Company is led by highly experienced and prominent serial entrepreneurs in the healthcare industry.
Dimerix Bioscience Pty Ltd
Escala Therapeutics, Inc.
Share price 2.38
Market cap $116m USD
FibroStatin
SLGlaxoSmithKline
Share price $42.50
Market cap 106.4b
Mallinckrodt Plc
Share price $73.07
Merck KGaA
Share price $62.49
Market cap $173m
Omeros CorporationPfizer Inc.Pharmalink ABRetrophin Inc.Rigel Pharmaceuticals, Inc.Shire PlcToray Industries, Inc.Variant Pharmaceuticals, Inc.
Ann: Positive interim analysis of DMX-200 phase II data-DXB.AX, page-126
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.5¢ |
Change
0.015(3.95%) |
Mkt cap ! $217.2M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 40.5¢ | 37.0¢ | $863.2K | 2.230M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 56796 | 39.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 15592 | 1 |
View Market Depth
| Last trade - 15.59pm 08/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |